Eleven months after launching with $60 million in hand, Ventus Therapeutics raised another $100 million to drive the company’s pipeline toward the clinic.

Swiss pharma giant Roche acquired Ireland’s Inflazome and the company’s NLRP3 inflammasome inhibitors aimed at multiple inflammatory diseases.